A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
AstraZeneca
BeiGene
Checkpoint Therapeutics, Inc.
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
SCRI Development Innovations, LLC
Canadian Cancer Trials Group
Nektar Therapeutics
Eli Lilly and Company
AbbVie
AstraZeneca
University of California, San Diego
AstraZeneca
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CanBas Co. Ltd.
University Hospital of Crete
Providence Health & Services
Wuhan University